Madrigal Pharmaceuticals (MDGL) reported a Q1 net loss Thursday of $3.32 per diluted share, narrower than a loss of $7.38 a year earlier.
Analysts polled by FactSet expected a loss of $3.75.
Revenue for the quarter ended March 31 was $137.3 million. The company didn't provide a year-earlier figure. Analysts surveyed by FactSet expected $114.7 million.
The company said it had cash, cash equivalents, restricted cash and marketable securities of $848.1 million as of March 31, compared with $931.3 million as of Dec. 31.
The company's shares were up more than 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.